Stocks Health care XLO
NASDAQ · Health careXilio Therapeutics, Inc. (XLO)
Xilio Therapeutics, Inc. brought in $64.1M of revenue over the twelve months to June 30, 2026. It posted a net loss of $21.8M. In fiscal 2025 capital spending exceeded operating cash flow by $5.5M. At June 30, 2026 it held $136M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 12, 2026.
Key facts about Xilio Therapeutics, Inc.
- Net worth
- Xilio Therapeutics, Inc. has a market value (market cap) of $56.1M at the latest share price, and shareholders' equity of $72.3M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $43.8M (+589.9% year on year), with a net loss of $35M. Over the 12 months to June 30, 2026: revenue $64.1M, net loss $21.8M.
- Cash flow
- In fiscal 2025 operations used $5M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 12, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Xilio Therapeutics, Inc.'s next report is expected around November 12, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What Xilio Therapeutics, Inc. does
Xilio Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker XLO.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $43.8M | -$35M | -$4.19 | -$5.5M |
| 2024 | $6.3M | -$58.2M | -$15.24 | -$18.4M |
| 2023 | n/a | -$76.4M | -$38.87 | -$69.1M |
| 2022 | n/a | -$88.2M | -$45.02 | -$77.6M |
| 2021 | n/a | -$75.8M | -$189.03 | -$81.9M |
| 2021 | n/a | -$55.2M | -$1,473.95 | -$38.3M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where XLO ranks in Health care
Latest SEC filings
What Xilio Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 12, 2026
- August 12, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 131% to $18.7M versus the same quarter last year; diluted EPS -$0.33 versus -$2.30.
- August 12, 2026
- June 12, 2026
- May 27, 2026
- May 15, 2026Passive stake (5% or more) SCHEDULE 13G
- May 15, 2026Passive stake changed SCHEDULE 13G/A
- May 15, 2026Passive stake changed SCHEDULE 13G/A
- May 15, 2026Passive stake (5% or more) SCHEDULE 13G
Insider trades
What the people running Xilio Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| March 26, 2026 | Shannon James SamuelDirector | Bought | 5,000 | $43.9K |
| January 2, 2026 | Frankenfield Christopher JamesChief Financial Officer | Soldpre-planned (10b5-1) | 7,030 | $4.5K |
| January 2, 2026 | Brennan Kevin M.SVP, FINANCE AND ACCOUNTING | Soldpre-planned (10b5-1) | 1,826 | $1.2K |
| January 1, 2026 | Russo RenePRESIDENT AND CEO, Director | Exercised options | 44,250 | - |
| January 1, 2026 | Frankenfield Christopher JamesChief Financial Officer | Exercised options | 19,375 | - |
| January 1, 2026 | Brennan Kevin M.SVP, FINANCE AND ACCOUNTING | Exercised options | 5,000 | - |
| January 1, 2026 | Luptakova KatarinaCHIEF MEDICAL OFFICER | Exercised options | 16,625 | - |
Who owns XLO
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Bain Capital Life Sciences Fund II, L.P.13G, passive | 9.99% | November 14, 2024 |
| BCLS II Equity Opportunities, LP13G, passive with 2 related filers | 9.99% | May 15, 2026 |
| Coastlands Capital LP13G, passive with 4 related filers | 9.99% | December 11, 2025 |
| Orbimed Advisors LLC13G, passive with 1 related filers | 9.99% | May 15, 2026 |
| Sirenia Capital Management LP13G, passive with 1 related filers | 9.9% | May 15, 2026 |
| StemPoint Capital LP13G, passive with 2 related filers | 9.5% | August 14, 2026 |
| Frazier Life Sciences Public Fund, L.P.13G, passive with 13 related filers | 6.7% | February 13, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 26 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 664,021 | 0 |
| Gilead Sciences, Inc. | 650,389 | 0 |
| Orbimed Advisors LLC | 592,300 | new |
| Frazier Life Sciences Management, L.P. | 422,505 | 0 |
| Stonepine Capital Management, LLC | 225,994 | +161,832 |
| Vanguard Capital Management LLC | 178,517 | +54,857 |
| Sio Capital Management, LLC | 152,464 | 0 |
| Adage Capital Partners GP, L.L.C. | 111,541 | new |
| Merck & Co., Inc. | 105,982 | 0 |
| Renaissance Technologies LLC | 64,153 | +14,587 |
| Morgan Stanley | 56,954 | -539 |
| Geode Capital Management, LLC | 39,055 | +1,858 |
| Citadel Advisors LLC | 25,950 | new |
| Vanguard Fiduciary Trust Co | 22,594 | -5,881 |
| Bridgeway Capital Management, LLC | 17,544 | new |
| Two Sigma Investments, LP | 14,544 | new |
| Velan Capital Investment Management LP | 14,285 | 0 |
| State Street Corp | 13,311 | 0 |
| Prelude Capital Management, LLC | 11,600 | new |
| BlackRock, Inc. | 8,757 | new |
Insiders
5 insiders reported holding 399,809 shares in total, about $3.4M at the last price.
| Holder | Shares |
|---|---|
| Russo RenePRESIDENT AND CEO, Director | 325,422 |
| Luptakova KatarinaCHIEF MEDICAL OFFICER | 33,250 |
| Frankenfield Christopher JamesChief Financial Officer | 24,766 |
| Shannon James SamuelDirector | 10,000 |
| Brennan Kevin M.SVP, FINANCE AND ACCOUNTING | 6,371 |
Questions about XLO
What does Xilio Therapeutics, Inc. do?
Xilio Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as XLO. Its shares trade on NASDAQ under the ticker XLO.
What is Xilio Therapeutics, Inc.'s net worth?
Xilio Therapeutics, Inc. has a market value (market cap) of $56.1M at the latest share price, and shareholders' equity of $72.3M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Xilio Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $21.8M on revenue of $64.1M.
How much revenue does Xilio Therapeutics, Inc. make?
Over the twelve months to June 30, 2026 Xilio Therapeutics, Inc. reported revenue of $64.1M.
When did Xilio Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 12, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from October 2, 2026.
When is Xilio Therapeutics, Inc.'s next earnings report?
Xilio Therapeutics, Inc.'s next report is expected around November 12, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare XLO with
Follow XLO
Get an email when Xilio Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Xilio Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.